Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [843]

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and...

Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )

OncoAlert and ecancer ASCO roundup - Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer ASCO roundup - Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer ASCO roundup - Day 1

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo...

Dr Joshua Sabari and Dr Anna Minchom

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )

mCRPC: Latest developments in diagnostics and combination therapies

Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor

mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally...

Dr Terence Friedlander - UCSF, San Francisco, USA

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

SMMART Program: A multi-omics tumour board with a focus on breast cancer

Dr Ben Kong - Oregon Health & Science University, Portland, USA

SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )

Clinical validation of a targeted methylation-based multi-cancer early...

Dr Eric Klein - Cleveland Clinic, Cleveland, USA

Clinical validation of a targeted methylation-based multi-cancer early detection test ( Dr Eric Klein - Cleveland Clinic, Cleveland, USA )

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than...

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

High-quality neoantigens are immunoedited in long-term survivors of pancreatic...

Prof Marta Luksza - Tisch Cancer Institute, New York, USA

High-quality neoantigens are immunoedited in long-term survivors of pancreatic cancer ( Prof Marta Luksza - Tisch Cancer Institute, New York, USA )

More from ecancer